| Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis P Savas, B Virassamy, C Ye, A Salim, CP Mintoff, F Caramia, R Salgado, ... Nature medicine 24 (7), 986-993, 2018 | 849 | 2018 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (6), 311-335, 2017 | 697 | 2017 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (5), 235-251, 2017 | 629 | 2017 |
| Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of … SJ Luen, R Salgado, S Fox, P Savas, J Eng-Wong, E Clark, A Kiermaier, ... The Lancet Oncology 18 (1), 52-62, 2017 | 310 | 2017 |
| The genomic landscape of breast cancer and its interaction with host immunity S Luen, B Virassamy, P Savas, R Salgado, S Loi The Breast 29, 241-250, 2016 | 260 | 2016 |
| Tissue-resident memory T cells in breast cancer control and immunotherapy responses A Byrne, P Savas, S Sant, R Li, B Virassamy, SJ Luen, PA Beavis, ... Nature Reviews Clinical Oncology 17 (6), 341-348, 2020 | 205 | 2020 |
| Combined CDK4/6 and PI3Kα inhibition is synergistic and immunogenic in triple-negative breast cancer ZL Teo, S Versaci, S Dushyanthen, F Caramia, P Savas, CP Mintoff, ... Cancer research 77 (22), 6340-6352, 2017 | 176 | 2017 |
| Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy SJ Luen, R Salgado, MV Dieci, A Vingiani, G Curigliano, RE Gould, ... Annals of Oncology 30 (2), 236-242, 2019 | 175 | 2019 |
| Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer Z Kos, E Roblin, RS Kim, S Michiels, BD Gallas, W Chen, KK van de Vijver, ... NPJ breast cancer 6 (1), 17, 2020 | 137 | 2020 |
| Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer SJ Luen, P Savas, SB Fox, R Salgado, S Loi Pathology 49 (2), 141-155, 2017 | 136 | 2017 |
| Report on computational assessment of tumor infiltrating lymphocytes from the International Immuno-Oncology Biomarker Working Group M Amgad, ES Stovgaard, E Balslev, J Thagaard, W Chen, S Dudgeon, ... NPJ breast cancer 6 (1), 16, 2020 | 126 | 2020 |
| Clinical validity and utility of tumor-infiltrating lymphocytes in routine clinical practice for breast cancer patients: current and future directions L Wein, P Savas, SJ Luen, B Virassamy, R Salgado, S Loi Frontiers in oncology 7, 156, 2017 | 122 | 2017 |
| Checkpoint blockade in the treatment of breast cancer: current status and future directions L Wein, SJ Luen, P Savas, R Salgado, S Loi British journal of cancer 119 (1), 4-11, 2018 | 115 | 2018 |
| Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer S Dushyanthen, ZL Teo, F Caramia, P Savas, CP Mintoff, B Virassamy, ... Nature communications 8 (1), 606, 2017 | 109 | 2017 |
| Clinical implications of prospective genomic profiling of metastatic breast cancer patients CT van Geelen, P Savas, ZL Teo, SJ Luen, CF Weng, YA Ko, ... Breast Cancer Research 22, 1-13, 2020 | 39 | 2020 |
| Association of somatic driver alterations with prognosis in postmenopausal, hormone receptor–positive, HER2-negative early breast cancer: a secondary analysis of the BIG 1-98 … SJ Luen, R Asher, CK Lee, P Savas, R Kammler, P Dell’Orto, OM Biasi, ... JAMA oncology 4 (10), 1335-1343, 2018 | 37 | 2018 |
| Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer B Virassamy, F Caramia, P Savas, S Sant, J Wang, SN Christo, A Byrne, ... Cancer Cell 41 (3), 585-601. e8, 2023 | 36 | 2023 |
| Abstract CT007: PETRA: first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations TA Yap, SA Im, AM Schram, A Sharp, J Balmana, RD Baird, JS Brown, ... American Association for Cancer Research (AACR), 2022 | 30 | 2022 |
| A Malignant Neoplasm From the Jejunum With a MALAT1-GLI1 Fusion and 26-Year Survival History OWJ Prall, CRE McEvoy, DJ Byrne, A Iravani, J Browning, DYH Choong, ... International journal of surgical pathology 28 (5), 553-562, 2020 | 28 | 2020 |
| Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials J Hudeček, L Voorwerk, M van Seijen, I Nederlof, M de Maaker, ... NPJ Breast Cancer 6 (1), 15, 2020 | 28 | 2020 |
